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Abstract: The therapeutic potential of Sargassum siliquosum grown in Australian tropical waters
was tested in a rat model of metabolic syndrome. Forty-eight male Wistar rats were divided into
four groups of 12 rats and each group was fed a different diet for 16 weeks: corn starch diet (C);
high-carbohydrate, high-fat diet (H) containing fructose, sucrose, saturated and trans fats; and C
or H diets with 5% S. siliquosum mixed into the food from weeks 9 to 16 (CS and HS). Obesity,
hypertension, dyslipidaemia, impaired glucose tolerance, fatty liver and left ventricular fibrosis
developed in H rats. In HS rats, S. siliquosum decreased body weight (H, 547 ± 14; HS, 490 ± 16 g),
fat mass (H, 248 ± 27; HS, 193 ± 19 g), abdominal fat deposition and liver fat vacuole size but did not
reverse cardiovascular and liver effects. H rats showed marked changes in gut microbiota compared
to C rats, while S. siliquosum supplementation increased gut microbiota belonging to the family
Muribaculaceae. This selective increase in gut microbiota likely complements the prebiotic actions of
the alginates. Thus, S. siliquosum may be a useful dietary additive to decrease abdominal and liver
fat deposition.
Keywords: Sargassum siliquosum; brown seaweed; fucoidans; alginates; gut microbiota; metabolic
syndrome
1. Introduction
Seaweeds are now a major industry worldwide, including a rediscovery of regional
seaweed cuisines [1], but there are risks involved with some edible seaweeds [2]. The brown
seaweed, Saccharina japonica, accounts for more than one-third of total world production,
with over 11 million tonnes in 2018 [3]. Brown seaweeds have many commercial uses,
including as food for human consumption [4], improving growth and meat quality of
livestock [5], as a substrate for bioethanol production [6], as biostimulants for agricultural
use [7] and as cation exchangers for wastewater remediation [8]. Further, the management
of metabolic syndrome may be improved by some brown seaweeds, including Ascophyllum
nodosum and Fucus vesiculosis [9].
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Brown seaweeds also include the Sargassum genus that inhabits the Atlantic, Pacific
and Indian oceans, including temperate, subtropical and tropical habitats; its biogeography
suggests an origin at around 6.7 million years ago [10]. Sargassum species, primarily
S. natans and S. fluitans, produced more than 20 million metric tonnes of biomass extending
from West Africa to the Gulf of Mexico in 2018 [11]. Further, massive mats of S. horneri
have occurred since 2015 off the southeastern coast of Korea [12]. However, value-adding
pathways have been proposed for these golden tide seaweeds [13]. Sargassum (fusiforme)
is already a traditional and highly prized food in Asia, with commercial aquaculture
production of 54,624 tonnes of S. fusiforme in 2017 at a value of USD 28.7 million [14].
Further, Sargassum species produce many compounds with a wide range of biological
actions, including protection against heat, pollution, stress, decreased oxygen concentration
and ultraviolet radiation [15].
Commercial Sargassum species such as S. fusiforme contain alginates, laminarins and
fucoidans as the major polysaccharides [16]; the xanthophyll, fucoxanthin, gives the brown
seaweeds their colour. The species tested in this project, S. siliquosum, is found predom-
inantly in the Sargasso Sea (western North Atlantic Ocean) and the Coral Sea (off the
northeast coast of Australia) [17].
Functional foods are claimed to ameliorate metabolic syndrome [18], defined as a
clustering of conditions that increase the risk of developing cardiovascular disease and type
2 diabetes; these factors include obesity, dyslipidaemia, hypertension, impaired glucose
tolerance and fatty liver [19]. However, the effectiveness of Sargassum as a functional
food has not been defined, although Sargassum products have shown effectiveness against
metabolic diseases [20]. Sargassum species could exhibit antioxidant responses such as nitric
oxide scavenging [21] and anti-inflammatory responses including reduced paw volumes
in carrageenan-induced oedema [22]; both actions may be useful in metabolic syndrome.
Further, fucoxanthin present in the whole seaweed may decrease obesity by modulating
the expression of uncoupling protein-1; in a human trial, body weight was reduced by
5.5 kg following treatment with fucoxanthin at 2.4 mg/day for 16 weeks [23]. Fucoxanthin
concentrations in brown seaweeds such as Sphaerotrichia divaricata [24] may be sufficient to
improve physiological parameters when added to foods [25]. However, no studies have
investigated Sargassum species on the range of pathophysiological changes that characterise
metabolic syndrome.
We have reported that sulphated polysaccharides from the red seaweed Sarconema fil-
iforme [26] and the green seaweed Caulerpa lentillifera [27] reversed the cardiovascular,
metabolic and liver changes induced by a high-carbohydrate, high-fat diet in rats. Our
hypothesis for this project was that the brown seaweed, S. siliquosum, as a source of
non-sulphated (alginates and laminarins) and sulphated polysaccharides (fucoidans) and
fucoxanthin, also reverses the signs of metabolic syndrome in this rat model [28]. This
seaweed was chosen as it may be amenable to cultivation in tropical areas of Australia [29].
To test our hypothesis, we measured the parameters related to metabolic syndrome follow-
ing chronic dietary intervention with S. siliquosum, including the structure and function
of heart and liver, plasma biochemistry, glucose and insulin responses and body compo-
sition. Further, we characterised the changes in the composition of gut microbiota after
seaweed treatment, as functional foods have the potential to reverse the changes induced
in obesity [30,31]. The major mechanisms for possible responses to S. siliquosum could
include the prebiotic actions of polysaccharides including fucoidans and alginates in the
colon by reducing the intestinal absorption of carbohydrates and fats and also changing
the gut microbiota, in combination with the anti-inflammatory effects of fucoxanthin [25].
The combination of these polysaccharides with fucoxanthin in the dried seaweed may also
suppress the infiltration of inflammatory cells into the heart and liver.
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2. Materials and Methods
2.1. Sargassum siliquosum Biomass Collection
S. siliquosum was collected by snorkel from a rocky reef at approximately 2 m depth
in Nelly Bay, Magnetic Island, QLD, Australia (19.1708◦ S, 146.8471◦ E), on 28 November
2017, and immediately transported to James Cook University, Townsville, QLD, Aus-
tralia. Twelve specimens with intact holdfasts and fresh new growth were photographed
(Figure 1) and selected for genetic barcoding. The remaining fresh biomass was briefly
rinsed in batches in filtered seawater, followed by freshwater to remove sand, debris,
invertebrates and epiphytes. The rinsed biomass was dried at 60 ◦C for 48 h, sorted to
remove remaining foreign matter such as coral rubble in holdfasts, milled to 1 mm and
homogenised. The biomass was stored with silica desiccant in vacuum-sealed bags at 4 ◦C
until processing for experiments.
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Figure 1. Sargassum siliquosum specimen with intact holdfasts and fresh new growth.
2.2. Genetic Barcoding
One blade from each of the twelve specimens selected for molecular barcoding was
excised and l t claved seawater, using a soft paintbrush to remov debris
and epiphytes. Each blade was ried to remove excess water and subsequently kept in
individually labelled zip-lock bags with 50 g of silica beads to desiccate. Dried sampl s
w re sent to Victoria University of Wellington, N w Zealand, for DNA extraction using
a modified CTAB protocol [32]. The molecular marker mitochondrial gene cytochrome
oxidase I (COI) was used to obtain sequences to assign Sargassum specimens to a genetic
species group. The forward primer GazF2 (5′ ACC Y A GATATWGGTAC3′) and
reverse primer GazR2 (5′ GATG CC AR CCAAAA3′) were used [33]. Maximum
likelihood (ML) phylogenetic trees were constructed in Iqtree ith sequences downloaded
from Genbank.
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2.3. Compositional Analyses
All analyses were performed on five subsamples (n = 5) of milled and homogenised
material, except for amino acid and constituent sugar analyses (n = 3) and fibre analysis
(n = 2). For sugar analysis, hydrolysis of the biomass (10 mg) was performed in a two-
step process: step 1: hydrolysis in 300 µL of 72% sulphuric acid at 20 ◦C for 1 h; step 2:
hydrolysis in 3.6 mL of 1M sulphuric acid at 100 ◦C for 2 h [34]. Sugar hydrolysates were
derivatised with 1-phenyl-3-methyl-5-pyrazolone (PMP) by a modified procedure [35].
Hydrolysates (40 µL) were neutralised with either 80 µL 1M NaOH prior to the addition of
400 µL of PMP-derivatising reagent (250 mM PMP and 400 mM ammonia in type 1 water)
or 40 µL of 2-deoxy-glucose solution (10 mg/mL in type 1 water). This mixture was then
heated on a magnetic stirrer at 700C for 90 min. Derivatised samples were neutralised
by addition of 400 µL of 0.8M formic acid followed by extraction of unbound PMP with
750 µL of chloroform. The aqueous layer was isolated and clarified by centrifugation
(13,000 rpm for 5 min; Heraeus Pico 17 Thermo Scientific Centrifuge) prior to HPLC
analysis. HPLC analysis was carried out with a Shimadzu LC-20AD Prominence fitted
with a Restek Raptor C18 column (5 µm particle size, 150 mm × 4.6 mm; Cat # 9314565)
with a flow rate of 0.8 mL/min and oven temperature of 40 0C. Derivatised sugar standards
or sample hydrolysates (5 µL) were injected and eluted with solvent A (0.1 M phosphate
buffer at pH 7 in 10% acetonitrile) and solvent B (0.1 M phosphate buffer at pH 7 in
17% acetonitrile) with the following gradient programme: 25% B 0–15 min, 25–100% B at
15–40 min, 100% B 40–55 min, 25% B 55–60 min. Constituent sugars were quantified using
PMP-derivatised calibration standards (0–10 mg/L) of fucose, galactose, glucose, mannose,
rhamnose, xylose, mannuronic acid, guluronic acid, glucuronic acid and galacturonic acid.
Proximate and elemental composition, trace elements, metals and metalloids, soluble and
insoluble fibre were analysed as previously described [36]. Total lipids were quantified
gravimetrically following extraction (60 ◦C, 1 h) of 200 mg (±0.1 mg) biomass in 5 mL
chloroform:methanol (2:1, v:v). The extract was filtered, washed with 0.9% NaCl (w:v),
allowed to separate into two phases, and the lower (organic) phase was collected for
evaporation under nitrogen and subsequently weighed to give the total lipid content [37].
Fatty acids were simultaneously extracted and transesterified by heating (100 ◦C, 1 h)
50 mg (±0.1 mg) biomass in 2 mL methylation reagent (methanol, acetyl chloride, 20:1
(v/v)) with 300 µL nonadecanoic acid (C19H38O2; >99%, Sigma-Aldrich, Castle Hill, NSW,
Australia) as internal standard. After cooling, 1 mL of hexane and 2 mL of deionised water
were added, and the upper (hexane) phase was collected for analysis by GC–MS [37]. Total
xanthophyll content was determined using ultraviolet–visible spectral peaks identified as
xanthophyll carotenoids based on common and characteristic spectra. Fucoxanthin content
was analysed using HPLC (diode-array detection at 450 nm) at Southern Cross University,
Lismore, NSW, Australia.
2.4. Rats and Diets
Male Wistar rats (8–9 weeks old; 336 ± 2 g, n = 48) were sourced and housed as
in previous studies [26,27] before being randomly divided into four groups (12 rats per
group). Two groups received either corn starch or high-carbohydrate, high-fat diets (C and
H, respectively) [28] for the full 16 weeks. The remaining groups received C and H diets
for the first eight weeks and then received C or H diet with 5% S. siliquosum for the final
eight weeks (CS and HS, respectively). Detailed composition of diets has been described in
our published study [28].
2.5. Rat Measurements
The interventions and measured parameters are given in Figure 2. Rats were anaes-
thetised using isoflurane for measurements of body composition using dual-energy X-ray
absorptiometry, systolic blood pressure and abdominal circumference measurement [26].
Oral glucose and insulin tolerance tests and indirect calorimetry were performed as previ-
ously described [28,38]. Following euthanasia, heparin was injected before blood collection,
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centrifugation, plasma isolation and analysis and then diastolic stillness measurements,
organ weights, thoracic aortic responses and histological analyses [28].
Nutrients 2021, 13, x FOR PEER REVIEW 5 of 18 
 
 
Oral glucose and insulin tolerance tests and indirect calorimetry were performed as pre-
viously described [28,38]. Following euthanasia, heparin was injected before blood collec-
tion, centrifugation, plasm  isol tion and analysis and then diastolic stilln ss measure-
ments, organ weights, th racic aortic responses and histological analyses [28]. 
 
Figure 2. Study design to identify effects of Sargassum siliquosum intervention. C, rats fed with corn 
starch diet; CS, rats fed with corn starch diet + 5% Sargassum siliquosum; H, rats fed with high-car-
bohydrate, high-fat diet; HS, rats fed with high-carbohydrate, high-fat diet + 5% Sargassum sili-
quosum. 
Post euthanasia, two or three faecal pellets were collected from the colon of each rat 
and processed as described previously to obtain gut microbiota composition [26,27]. Data 
were presented and analysed for statistical significance as detailed in previous studies 
[26,27]. 
3. Results 
3.1. Sargassum siliquosum Identification and Compositional Analyses 
DNA barcoding using the cytochrome oxidase subunit 1 (COI) gene was used for 
identification of the Sargassum samples collected. Sequences could be generated for 9 (out 
of 10) specimens and all sequences were identical. A phylogenetic tree was compiled from 
comparison with sequences downloaded from Genbank. A trimmed phylogenetic tree 
(Figure 3; full tree in Supplementary Figure S1) shows a clustering, with moderate boot-
strap support (53%), of similar Sargassum species; these Genbank accessions include sev-
eral named Sargassum species (S. ilicifolium, S. integerrimum) including S. siliquosum. The 
COI sequences of this grouping were identical, except for our samples and S. siliquosum, 
which shared a single synapomorphy. Based on these data and distributional data, we 
identified this species as S. siliquosum. These samples of S. siliquosum contained (in % of 
dry weight) 57.8% carbohydrate (11 mol% fucose, 24.4 mol% glucose, 26.4 mol% mannu-
ronic acid and 24.2 mol% guluronic acid), 1.7% lipid, 4.02% protein, 41.4% dietary fibre 
including 33.3% as soluble fibre with 7.5% K, 1.9% Ca, 1.2% Na and 0.97% S as the major 
elements (Tables 1 and 2; Supplementary Tables S1 and S2). Hydrolysates of Sargassum 
biomass indicated a total of 9.47% w/w sugars, with high contents of mannuronic acid and 
guluronic acid and glucose, consistent with the presence of alginate and storage carbohy-
drates/cellulose, respectively. Fucose was present at 0.91% w/w, consistent with the pres-
ence of fucoidan at ≥1.5% w/w as the monosulphated sodiated salt (Table 1). In S. sili-
quosum, glutamic acid and aspartic acid were the most common amino acids (Supplemen-
tary Table S1) and potassium and calcium the most common elements (Supplementary 
Table S2). Total xanthophyll content was 0.00746% w/w and fucoxanthin content was 
0.00058% w/w based on HPLC data (Figure 4). 
. t y design to identify effects of Sarg ssum siliquosum intervention. C, rats fed with corn starch
diet; CS, rats fed with corn starch diet +5% Sargassum siliquosum; H, rats fed with high-carbohydrate,
high-fat diet; HS, rats fed with high-carbohydrate, high-fat diet +5% Sargassum siliquosum.
Post euthanasia, two or three faecal pellets were collected from the colon of each
rat and processed as described previously to obtain gut microbi ta compositi n [26,27].
Data were present d and analysed for sta istical significance as detailed in previous
studies [26,27].
3. Results
.1. Sargassum siliquosum Identification and Compositional Analyses
DNA barcoding sing the cyt chrome oxidase subunit 1 (COI) gene was used for
identification of the Sargassum samples collected. Sequences could be generated for 9 (out
of 10) specimens and all sequences were identical. A phylogenetic tree was compiled
from comparison with sequences downloaded from Genbank. A trimmed phylogenetic
tree (Figure 3; full tree in Supplementary Figure S1) shows a clustering, with moderate
bootstrap support (53%), of similar Sargassum species; these Genbank accessions include
several named Sargassum species (S. ilicifolium, S. integerrimum) including S. siliquosum. The
COI sequences of this grouping were identical, except for our samples and S. siliquosum,
which shared a single synapomorphy. Based on these data and distributional data, we
identified this species as S. siliquosum. These samples of S. siliquosum contained (in % of
dry weight) 57.8% carbohydrate (11 mol% fucose, 24.4 mol% glucose, 26.4 mol% man-
nuronic acid and 24.2 mol% guluronic acid), 1.7% lipid, 4.02% protein, 41.4% dietary fibre
including 33.3% as soluble fibre with 7.5% K, 1.9% Ca, 1.2% Na and 0.97% S as the major
elements (Tables 1 and 2; Supplementary Tables S1 and S2). Hydrolysates of Sargassum
biomass indicated a total of 9.47% w/w sugars, with high contents of mannuronic acid
and guluronic acid and glucose, consistent with the presence of alginate and storage car-
bohydrates/cellulose, respectively. Fucose was present at 0.91% w/w, consistent with
the presence of fucoidan at ≥1.5% w/w as the monosulphated sodiated salt (Table 1). In
S. siliquosum, glutamic acid and aspartic acid were the most common amino acids (Supple-
mentary Table S1) and potassium and calcium the most common elements (Supplementary
Table S2). Total xanthophyll content was 0.00746% w/w and fucoxanthin content was
0.00058% w/w based on HPLC data (Figure 4).
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Figure 4. Chromatograms using diode-array detection to estimate xanthophyll (total) and fucoxanthin concentrations in
Sargassum siliquosum.
3.2. Physiological Parameters
Metabolic changes were more marked than cardiovascular or liver changes following
intervention with S. siliquosum. During weeks 9–16, the food consumption was unchanged
in C and CS, and in H and HS (Table 3; Figure 5). CS and HS rats drank more water
than their respective controls, C and H (Table 3, Figure 5). During weeks 9–16, there was
no difference in energy intake between C and CS rats or H and HS rats. After sixteen
weeks of feeding, the body weight of H rats was higher than C rats; HS rats had lower
body weights than H rats. There was no difference in lean mass across all groups. Fat
mass was higher in H rats compared to C rats, which were similar to CS rats. HS rats had
decreased retroperitoneal, liver and whole-body fat compared to H rats (Table 3). In HS
rats, there were no changes in lipid profile or glucose and insulin metabolism compared to
H rats. S. siliquosum did not affect the plasma triglyceride concentrations in HS and CS rats
compared to H and C rats, respectively, whereas plasma total cholesterol concentrations
were unaffected by diet or treatment (Table 3). H diet increased basal blood glucose
concentrations compared to C diet but S. siliquosum did not change basal blood glucose
concentrations or blood glucose area under the curve (Table 3).
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Table 3. Responses to Sargassum siliquosum.




Body weight 0 weeks, g 337 ± 1 338 ± 1 339 ± 1 338 ± 1 0.38 1.00 0.38
Body weight 8 weeks, g 366 ± 7 b 369 ± 5 b 445 ± 10 a 461 ± 13 a <0.0001 0.39 0.55
Body weight 16 weeks, g 388 ± 10 c 384 ± 10 c 547 ± 14 a 490 ±16 b <0.0001 0.047 0.08
Lean mass 16 weeks, g 292 ± 15 282 ± 6 299 ± 12 281 ± 10 0.78 0.20 0.71
Fat mass 16 weeks, g 75 ± 15 c 86 ± 8 c 248 ± 27 a 193 ± 19 b <0.0001 0.24 0.08
Food intake 0–8 weeks, g/day 43.2 ± 2.2 a 44.2 ± 1.0 a 26.6 ± 1.1 b 26.4 ± 1.0 b <0.0001 0.76 0.65
Food intake 9–16 weeks, g/day 44.0 ± 1.2 a 41.1 ± 0.9 a 23.9 ± 0.9 b 22.3 ± 0.6 b <0.0001 0.022 0.49
Xanthophylls intake (total), mg/kg/day - 0.40 ± 0.01 - 0.17 ± 0.01 - - -
Fucoxanthin intake, mg/kg/day - 0.031 ± 0.001 - 0.013 ± 0.001 - - -
Alginate intake, mg/kg/day - 1764 ± 15 - 749 ± 9 - - -
Fucoidan intake, mg/kg/day - 80.2 ± 0.8 - 34.1 ± 10.4 - - -
Iodine, mg/kg/day - 41 ± 1 - 17 ± 1 - - -
Polyunsaturated fatty acid intake, mg/kg/day - 26.2 ± 0.2 - 11.1 ± 0.1 - - -
Water intake 0–8 weeks, g/day 31.8 ± 1.6 31.8 ± 2.0 32.4 ± 1.4 29.1 ± 1.2 0.57 0.37 0.37
Water intake 9–16 weeks, g/day 21.7 ± 1.4 c 28.5 ± 0.7 b 28.8 ± 1.3 b 34.8 ± 1.4 a <0.0001 <0.0001 0.76
Energy intake 0–8 weeks, kJ/day 485 ± 25 b 496 ± 11 b 607 ± 19 a 584 ± 20 a <0.0001 0.76 0.39
Energy intake 9–16 weeks, kJ/day 470 ± 13 b 457 ± 6 b 536 ± 15 a 534 ± 13 a <0.0001 0.55 0.66
Feed efficiency 9–16 weeks, g/kJ 0.05 ± 0.01 b 0.03 ± 0.01 b 0.19 ± 0.02 a 0.05 ± 0.01 b 0.0001 0.08 0.042
Abdominal circumference 16 weeks, cm 18.7 ± 0.5 b 18.5 ± 0.2 b 21.5 ± 0.2 a 22.0 ± 0.5 a <0.0001 0.73 0.42
Body mass index, g/cm2 0.61 ± 0.03 b 0.65 ± 0.01 b 0.81 ± 0.02 a 0.75 ± 0.02 a <0.0001 0.62 0.019
Retroperitoneal fat, mg/mm 210 ± 20 c 218 ± 13 c 673 ± 54 a 495 ± 50 b <0.0001 0.052 0.034
Epididymal fat, mg/mm 89 ± 11 b 65 ± 7 b 250 ± 36 a 115 ± 15 b <0.0001 <0.0001 0.003
Omental fat, mg/mm 139 ± 14 b 165 ± 9 b 325 ± 34 a 272 ± 22 a <0.0001 0.53 0.07
Total abdominal fat, mg/mm 437 ± 42 c 448 ± 25 c 1107 ± 57 a 907 ± 71 b <0.0001 0.12 0.08
Visceral adiposity, % 5.2 ± 0.5 b 5.3 ± 0.2 b 9.3 ± 1.1 a 8.3 ± 0.6 a <0.0001 0.47 0.38
Liver wet weight, mg/mm 261 ± 11 b 244 ± 10 b 380 ± 12 a 376 ± 14 a <0.0001 0.44 0.63
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Systolic blood pressure 8 weeks, mmHg 125 ± 4 b 121 ± 2 b 137 ± 3 a 134 ± 3 a 0.0003 0.27 0.87
Systolic blood pressure 16 weeks, mmHg 123 ± 2 b 122 ± 2 b 138 ± 3 a 135 ± 4 a 0.0003 0.57 0.77
Left ventricle + septum, mg/mm 22.9 ± 1.1 22.8 ± 0.7 25.2 ± 1.1 23.0 ± 0.7 0.17 0.20 0.25
Right ventricle, mg/mm 4.5 ± 0.7 3.9 ± 0.3 5.3 ± 0.2 5.3 ± 0.2 0.004 0.41 0.41
Left ventricular diastolic stiffness, κ 22.1 ± 0.8 b 22.9 ± 0.7 b 30.5 ± 1.2 a 29.4 ± 1.3 a <0.0001 0.90 0.42
Left ventricular collagen area, % 10 ± 2 b 11 ± 3 b 33 ± 3 a 29 ± 5 a 0.0003 0.67 0.49
Metabolic variables
Plasma total cholesterol, mmol/L 1.56 ± 0.08 1.68 ± 0.06 1.57 ± 0.10 1.86 ± 0.19 0.53 0.18 0.57
Plasma triglycerides, mmol/L 0.43 ± 0.02 b 0.42 ± 0.04 b 1.88 ± 0.31 a 1.54 ± 0.28 a <0.0001 0.40 0.43
Alanine transaminase, U/L 34 ± 4 53 ± 6 38 ± 2 48 ± 6 0.94 0.028 0.48
Aspartate transaminase, U/L 116 ± 2 150 ± 19 120 ± 12 142 ± 20 0.92 0.18 0.77
Liver inflammatory cells, cells/200 µm2 6 ± 1 b 7 ± 1 b 25 ± 2 a 26 ± 3 a <0.0001 0.62 1.00
Liver fat vacuoles area, fat vacuoles/200 µm2 13.1 ± 1.7 c 15.6 ± 2.4 c 88.6 ± 3.4 a 55.2 ± 2.9 b <0.0001 <0.0001 <0.0001
Oral glucose tolerance test
Basal blood glucose 0 weeks, mmol/L 2.6 ± 0.1 2.6 ± 0.1 2.6 ± 0.2 2.7 ± 0.1 0.70 0.70 0.70
Area under the curve 0 weeks, mmol/L ×minute 632 ± 30 594 ± 20 606 ± 19 552 ± 12 0.11 0.033 0.70
Basal blood glucose 8 weeks, mmol/L 2.9 ± 0.2 b 2.6 ± 0.1 b 3.3 ± 0.1 a 3.5 ± 0.1 a <0.0001 0.70 0.058
120-minute blood glucose 8 weeks, mmol/L 3.5 ± 0.2 b 3.7 ± 0.1 b 5.0 ± 0.1 a 5.2 ± 0.2 a <0.0001 0.27 1.00
Area under the curve 8 weeks, mmol/L ×minute 530 ± 15 b 537 ± 9 b 657 ± 22 a 682 ± 15 a <0.0001 0.31 0.57
Basal blood glucose 16 weeks, mmol/L 2.8 ± 0.2 3.0 ± 0.2 3.3 ± 0.2 3.4 ± 0.1 0.55 0.84 0.95
120-minute blood glucose 16 weeks, mmol/L 3.9 ± 0.2 b 3.7 ± 0.1 b 4.8 ± 0.3 a 4.5 ± 0.1 a <0.0001 0.13 0.76
Area under the curve 16 weeks, mmol/L × minute 501 ± 21 b 523 ± 14 b 617 ± 25 a 604 ± 9 a <0.0001 0.79 0.29
Insulin tolerance test
120-minute blood glucose 8 weeks, mmol/L 2.9 ± 0.4 b 2.7 ± 0.2 b 4.5 ± 0.3 a 4.4 ± 0.2 a <0.0001 0.58 0.85
Area under the curve 8 weeks, mmol/L ×minute 247 ± 58 b 234 ± 32 b 408 ± 21 a 390 ± 18 a <0.0001 0.65 0.94
120-minute blood glucose 16 weeks, mmol/L 2.7 ± 0.3 b 3.3 ± 0.2 b 4.5 ± 0.4 a 4.3 ± 0.2 a <0.0001 0.46 0.14
Area under the curve 16 weeks, mmol/L × minute 208 ± 37 b 168 ± 27 b 404 ± 54 a 420 ± 28 a <0.0001 0.74 0.44
Values are presented as mean ± SEM, n = 10–12. Means in a row with unlike superscripts (a, b or c) differ, p < 0.05. C, rats fed with corn starch diet; CS, rats fed with corn starch diet + Sargassum siliquosum; H, rats
fed with high-carbohydrate, high-fat diet; HS, rats fed with high-carbohydrate, high-fat diet + Sargassum siliquosum.
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Systolic blood pressure of H and HS rats was higher than C and CS rats at 8 weeks
(Table 3). Systolic blood pressure and left ventricular diastolic stiffness in H rats were
higher than in C rats at 16 weeks. Intervention with S. siliquosum did not alter systolic
blood pressure or left ventricular stiffness (Table 3). Left ventricular wet weights with
septum and right ventricular wet weights were not different among the groups (Table 3).
Intervention with S. siliquosum did not alter noradrenaline-induced contraction or sodium
nitroprusside-induced relaxation responses of thoracic aorta, while acetylcholine-induced
relaxation was improved in HS rats compared to H rats (Figure 6). Left ventricles from
H rats showed infiltration of inflammatory cells and collagen deposition, whereas these
changes were absent in left ventricles from C rats; intervention with S. siliquosum did not
alter collagen deposition (Figure 7). Fat vacuole area and infiltration of inflammatory cells
were increased in livers from H rats compared to C rats; these parameters were reduced
in HS rats (Figure 7). Plasma activities of ALT and AST were unchanged between groups
(Table 3).
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Figure 7. Histological analysis of liver, heart, ileum and colon. (A–D) showing haematoxylin and eosin staining and (E–
H) showing oil red O staining to identify liver fat deposition; (I–L) showing haematoxylin and eosin staining to identify 
heart inflammation; (M–P) showing picrosirius red staining to identify heart fibrosis; (Q–T) showing haematoxylin and 
eosin stain of ileum and (U–X) showing haematoxylin and eosin stain of colon in rats fed with corn starch diet 
(A,E,I,M,Q,U), rats fed with corn starch diet + Sargassum siliquosum (B,F,J,N,R,V), rats fed with high-carbohydrate, high-
fat diet (C,G,K,O,S,W) and rats fed with high-carbohydrate, high-fat diet + Sargassum siliquosum (D,H,L,P,T,X). Fat cells = 
fc; inflammatory cells = ic; fibrosis = fb. Scale bar is 200 µm for (A–P) (20×) and 100 µm for (Q–X) (10×). 
3.3. Gut Structure and Microbiota 
The structures of the ileum and colon were unchanged by diet or intervention, de-
fined by crypt depth, villi length and goblet cells, and lack of inflammatory cell infiltration 
(Figure 7). 
For gut microbiota characterisation, a total of 799,215 quality-filtered sequences were 
clustered into 1307 zOTUs; Good’s coverage score of 99.69 ± 0.12% suggested full recovery 
of bacterial communities. Shannon’s diversity and richness indices were unchanged 
among the groups (Supplementary Figure S2). Diet and S. siliquosum affected the overall 
bacterial community structure individually as well as through their interaction (Figure 8; 
Supplementary Table S3). 
Figure 7. Histological analysis of liver, heart, ileum and colon. (A–D) showing haematoxylin
and eosin staining and (E–H) showing oil red O staining to identify liver fat deposition; (I–L)
showing haematoxylin and eosin staining to identify heart inflammation; (M–P) showing picrosirius
red staining to identify heart fibrosis; (Q–T) showing haematoxylin and eosin stain of ileum and
(U–X) showing haematoxylin and eosin stain of colon in rats fed with corn starch diet (A,E,I,M,Q,U),
rats fed with corn starch diet + Sargassum siliquosum (B,F,J,N,R,V), rats fed with high-carbohydrate,
high-fat diet (C,G,K,O,S,W) and rats fed with high-carbohydrate, high-fat diet + Sargassum siliquosum
(D,H,L,P,T,X). Fat cells = fc; inflammatory ells = ic; fibrosis = fb. Scale bar is 200 µm for (A–P) (20×)
and 100 µm for (Q–X) (10×).
3.3. Gut Structure and Microbiota
The structures of the ileum and colon were unchanged by diet or intervention, defined
by crypt depth, villi length and goblet cells, and lack of inflammatory cell infiltration
(Figure 7).
For gut microbiota characterisation, a total of 799,215 quality-filtered sequences were
clustered into 1307 zOTUs; Good’s coverage score of 99.69 ± 0.12% suggested full recovery
of bacterial communities. Shannon’s diversity and richness indices were unchanged
among the groups (Supplementary Figure S2). Diet and S. siliquosum affected the overall
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bacterial community structure individually as well as through their interaction (Figure 8;
Supplementary Table S3).
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were the most abundant bacterial classes in the faecal samples (Figure 9). Coriobacteriia, 
Melainabacteria, Deferribacteres, Saccharimonadia, Alphaproteobacteria, Deltaproteo-
bacteria, Gammaproteobacteria and Mollicutes were observed at lower abundance levels 
(<1%) in some faecal samples. A higher abundance of bacteria from the class Clostridia 
was observed for the H diet samples, and this was more pronounced for control groups 
(C: 43.45 ± 1.75%, H: 66.35 ± 5.26%, P = 0.0005) compared to groups supplemented with 
Sargassum (CS: 53.58 ± 8.73%, HS: 55.23 ± 8.40%) (Figure 9). Within the class Bacteroidia, 
there was an increase in the relative abundance of bacteria from the family Muribaculaceae 
in HS rats (24.34%) compared to H rats (10.35%) (P = 00063). Further information on the 
gut microbiota, including at genus level (Supplementary Figure S3), and changes due to 
diet intervention (Supplementary Tables S3–S6), are included in the Supplementary Infor-
mation. 
Figure 8. Multidimensional scaling plot for the Bray–Curtis dissimilarities of bacterial gut communi-
ties. C, rats fed with corn starch diet; CS, rats fed with corn starch diet + Sargassum siliquosum; H, rats
fed with high-carbohydrate, high-fat diet; HS, high-carbohydrate, high-fat diet + Sargassum siliquosum.
Actinobacteria, Bacteroidia, Bacilli, Clostridia, Erysipelotrichia and Verrucomicrobia
were the most abundant bacterial classes in the faecal samples (Figure 9). Coriobacteriia,
Melainabacteria, Deferribacteres, Saccharimonadia, Alphaproteobacteria, Deltaproteobac-
teria, Gammaproteobacteria and Mollicutes were observed at lower abundance levels
(<1%) in some faecal samples. A higher abundance of bacteria from the class Clostridia
was observed for the H diet samples, and this was more pronounced for control groups
(C: 43.45 ± 1.75%, H: 66.35 ± 5.26%, p = 0.0005) compared to groups supplemented with
Sargassum (CS: 53.58 ± 8.73%, HS: 55.23 ± 8.40%) (Figure 9). Within the class Bacteroidia,
there was an increase in the relative abundance of bacteria from the family Muribaculaceae
in HS rats (24.34%) compared to H rats (10.35%) (p = 00063). Further information on the gut
microbiota, including at genus level (Supplementary Figure S , and changes due t diet in-
tervent on (Supplementary Tabl s S3–S6), are inc ud d in the S pplementary Information.
Nutrients 2021, 13, 1754 13 of 18




Figure 9. Taxonomic profiles of bacterial communities of all faecal samples shown at the class level. 
C, rats fed with corn starch diet; CS, rats fed with corn starch diet + Sargassum siliquosum; H, rats fed 
with high-carbohydrate, high-fat diet; HS, rats fed with high-carbohydrate, high-fat diet + Sargassum 
siliquosum. 
4. Discussion 
Seaweeds containing complex mixtures of polysaccharides, peptides, pigments, min-
erals and omega-3 fatty acids have been shown to improve the signs of metabolic syn-
drome [39]. This study showed that 5% S. siliquosum supplementation in rats with diet-
induced metabolic syndrome decreased body weight and decreased retroperitoneal fat 
and liver fat but had no effect on systolic blood pressure, liver enzyme activities, lipid 
profile or glucose and insulin metabolism. Similar responses have been shown with other 
Sargassum species. As examples, S. thunbergii decreased obesity, serum insulin, triglycer-
ides and cholesterol in high-fat-diet-fed mice [40] and S. polycystum decreased damage to 
the liver in high-sugar, high-fat diet + streptozotocin-induced type 2 diabetic rats [41]. 
Sargassum species contain polysaccharides, predominantly (in decreasing content) al-
ginates, fucoidans and laminarans; these are the major constituents of the high fibre con-
tent of S. siliquosum [42] as in other brown seaweeds [43]. Oral intake of alginates leads to 
the formation of alginate gels in the small intestine, proposed as the most likely mecha-
nism for alginate-related slowed nutrient absorption leading to body weight loss [44]. In 
healthy humans, a dose of 9.9–15 g/day of sodium alginate increased satiety and reduced 
energy intake, suggesting that increased viscosity causing swelling of gastrointestinal con-
tents [45]. In a human trial using energy restriction (~1250 kJ/day) and 15 g/day of algi-
nates as a beverage for 12 weeks, body weight was reduced compared to the placebo 
group, mainly attributed to body fat reduction [46]. This human dose of 15 g alginates/day 
approximates to 3.1 g alginates/day in rats using the Reagan–Shaw scaling equation [47]. 
Fucoidan from S. fusiforme changed the gut microbiota, particularly by increasing the 
Bacteroidetes to Firmicutes ratio, to decrease streptozotocin-induced hyperglycaemia in 
mice [48]. Further, fucoidan from S. fusiforme decreased high-fat-diet-induced insulin re-
sistance in mice by activating the Nrf2 pathway, changing the gut microbiota and reduc-
ing intestinal inflammation [49]. Fucoidan supplementation of 100 mg/kg/day in high-fat-
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4. Discu sion
Seaweeds containing complex mixtures of polysaccharides, peptides, pigments, min-
erals and omega-3 fatty acids have been shown to improve the signs of metabolic syn-
drome [39]. This study showed that 5% S. siliquosum supplementation in rats with diet-
induced etabolic syndro e decreased body weight and decreased retroperitoneal fat and
liver fat but had no effect on systolic blood pressure, liver enzyme activities, lipid profile or
glucose and insulin metabolism. Similar responses have been shown with other Sargassum
species. As examples, S. thunbergii decreased obesity, serum insulin, triglycerides and
cholesterol in high-fat-diet-fed mice [40] and S. polycystum decreased damage to the liver
in high-sugar, high-fat diet + streptozotocin-induced type 2 diabetic rats [41].
Sargassum species contain polysaccharides, predominantly (in decreasing content)
alginates, fucoidans and laminarans; these are the major constituents of the high fibre
content of S. siliquosum [42] as in other brown seaweeds [43]. Oral intake of alginates
leads to the formation of alginate gels in the small intestine, proposed as the most likely
mechanism for alginate-related slowed nutrient absorption leading to body weight loss [44].
In healthy humans, a dose of 9.9–15 g/day of sodium alginate increased satiety and reduced
energy intake, suggesting that increased viscosity causing swelling of gastrointestinal
contents [45]. In a human trial using energy restriction (~1250 kJ/day) and 15 g/day of
alginates as a beverage for 12 weeks, body weight was reduced compared to the placebo
group, mainly attributed to body fat reduction [46]. This human dose of 15 g alginates/day
approximates to 3.1 g alginates/day in rats using the Reagan–Shaw scaling equation [47].
Fucoidan from S. fusiforme changed the gut microbiota, particularly by increasing
the Bacteroidetes to Firmicutes ratio, to decrease streptozotocin-induced hyperglycaemia
in mice [48]. Further, fucoidan from S. fusiforme decreased high-fat-diet-induced insulin
resistance in mice by activating the Nrf2 pathway, changing the gut microbiota and re-
ducing intestinal inflammation [49]. Fucoidan supplementation of 100 mg/kg/day in
high-fat-diet-fed rats improved blood lipid concentrations, decreased fat deposition in the
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liver and changed the gut microbiota [50]. However, this fucoidan dose was around three
times higher than the dose of around 34 mg/kg/day in the current study, so fucoidan is
unlikely to be the major bioactive compound in S. siliquosum.
Inhibiting digestive enzymes including α-amylase, α-glucosidase, pepsin and lipase
by seaweed polysaccharides and polyphenols may modulate obesity and cardiovascu-
lar risk [51]. In an in vitro study, S. siliquosum and S. polycystum inhibited angiotensin-
converting enzyme, α-amylase and α-glucosidase [52]. The role of these mechanisms in
the current study is unknown.
The biological responses could be caused by the xanthophyll, fucoxanthin. In high-
fat-diet-induced obese rats, fucoxanthin at doses of 0.083 and 0.167 mg/kg reduced white
adipose tissue weight, accumulation of hepatic lipid droplets and perirenal adipocyte
size [53]. These doses are 6–12 times higher than the fucoxanthin intake in the current
study, so it seems unlikely that the metabolic responses with S. siliquosum are primarily due
to the actions of fucoxanthin. The metabolic actions of phenolic acids and other xanthophyll
compounds present in this seaweed are unknown but they could be additive to responses
produced by the alginates.
Polyunsaturated fatty acids such as EPA and DHA decreased abdominal obesity and
total body fat in the same rat model of metabolic syndrome as the current study [54].
However, the dose of EPA or DHA in this study was approximately 1500 mg/kg/day, in
contrast to the dose of total polyunsaturated fatty acids in the current study of around
11 mg/kg/day. Thus, the changes in metabolic parameters following intervention with
S. siliquosum are unlikely to be due to an increased intake of polyunsaturated fatty acids.
Not unexpectedly, a diet with higher simple sugars and trans and saturated fats
changed the gut microbiome, similar to results in our previous study [26]. Supplementation
with S. siliquosum caused a further change in the gut microbiota, including an increase in
bacteria belonging to the family Muribaculaceae (also known as S24-7). Members of this
family are understudied but have recently been recognised for their versatile metabolism
of complex carbohydrates [55,56] and their potential for increased succinate, acetate and
propionate production [57]. Members of this family have also been linked to longevity in
rodents [58] and, based on our results, could decrease fat absorption or deposition, as these
parameters were reduced following intervention with S. siliquosum.
One potential mechanism would be that the polysaccharides from Sargassum act as
prebiotics to alter the changed gut microbiota in obesity, as shown by other seaweeds [59].
Alginates may be degraded by specific bacteria, including members of the Muribaculaceae,
thereby increasing concentrations of short-chain fatty acids, which could lead to human
health benefits [60]. Unsaturated alginate polysaccharides have been reported to act as
effective prebiotics by increasing beneficial gut bacteria and decreasing inflammogenic
bacteria in mice with high-fat-diet-induced obesity [61]. An improvement in gut health was
suggested by the in vitro fermentation of a polysaccharide from S. thunbergia by colonic
microbiota to short-chain fatty acids [62].
The current study could be extended by including the measurement of obesity-related
plasma and tissue biomarkers such as adiponectin and C-reactive protein, inflammatory
mediators such as TNF and functional changes in the colon such as short-chain fatty acid
production. These data could allow further interpretation of the mechanisms of action of
this seaweed.
5. Conclusions
The tropical Australian brown seaweed, S. siliquosum, reduced liver and abdominal fat
accumulation in high-carbohydrate high-fat fed rats. As this seaweed contains alginates as
the major polysaccharide, these alginates may act as prebiotics in the intestine to increase
concentrations of short-chain fatty acids. These actions are possibly complemented by an
increase in specific bacteria such as Muribaculaceae in the gut microbiome. These intestinal
changes could then lead to systemic anti-inflammatory effects in the heart and liver. We
conclude that the tropical Australian seaweed, S. siliquosum, should now be included with
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other local tropical seaweeds such as Sarconema filiforme [26] and Caulerpa lentillifera [27]
as dietary additives in clinical studies designed to measure improvements in the signs of
metabolic syndrome.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/nu13061754/s1, Figure S1: Genetic barcoding of Sargassum species: Maximum likelihood
tree of cytochrome oxidase I marker sequence data (full phylogenetic tree); Figure S2: (A) Shannon
diversity and (B) richness of faecal samples; Figure S3: Taxonomic profiles of bacterial communities
of all faecal samples shown at the genus level; Table S1: Fatty acids and amino acids content (% of
dry weight) in Sargassum siliquosum; Table S2: Metals and metalloids content (mg/kg of dry weight)
in Sargassum siliquosum; Table S3: PERMANOVAs based on Bray–Curtis similarity measure for
square-root transformed abundances; Table S4: Summarised differential zOTU abundance; Table S5:
Effects of diet on relative abundance of zOTUs; Table S6: Effects of treatment on relative abundance
of zOTUs.
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